C ytomegalovirus (CMV) is the most common pathogen affecting heart transplant recipients, and significantly influences outcome in these patients (1) (2) (3) . It has been demonstrated that CMV disease increases the morbidity of heart transplant recipients and predisposes them to acute rejection and transplant coronary artery disease (4 -10) . CMV has evolved mechanisms for avoiding detection by the host immune system, and consequently causes disease only when the immune system is suppressed as is the case after solid organ transplantation (11) (12) (13) . Accordingly, heart transplant patients are at risk for developing acute CMV disease that typically presents with evidence of organ dysfunction or a systemic viral syndrome. CMV disease is usually confirmed by CMV culture positivity, characteristic histological changes from the affected organ, or by polymerase chain reaction (PCR) from peripheral blood or tissue. Although it is recognized that leucopenia frequently occurs in patients with CMV disease, and might even be the presenting feature prompting further surveillance for active infection, there is a paucity of reports clearly documenting this phenomena in solid organ transplant recipients. A Medline search of published studies during the past 20 years failed to reveal any reports that address the time course of leucopenia in relation to CMV disease, either from clinical or mechanistic perspectives. Understanding the pathways leading to leucopenia in the setting of CMV disease might have important implications in light of the immunosuppressive action of the virus. For example, it has been demonstrated that patients with CMV disease are at increased risk for other opportunistic infections, and that effective prevention of CMV disease with antiviral drugs confers protection against fungal infection (14) .
In this study, we sought to document the changes in total and differential leukocyte count that occur prior to, and at the diagnosis of CMV disease in heart transplant patients. Furthermore, because studies have demonstrated the presence of asymptomatic CMV replication in organ transplant recipients, we also addressed the question of whether leucopenia occurs during subclinical CMV infection in patients during the initial year after transplant when activation of virus is most likely to occur. We also examined the effect on leukocyte count, of subclinical CMV infection in a cohort of long-term stable patients presenting for routine annual evaluation. In both of these latter two cohorts, subclinical infection was determined by the presence of CMV DNA using PCR to detect expression of CMV early immediate gene.
METHODS

Subjects and Measurements
A retrospective review of the medical records of heart transplant recipients from 1992 to 2001 was performed at our institution. We sought to identify a cohort of patients (Cases) who fulfilled diagnostic criteria for CMV disease as described below, and who had received their transplant during a period when the immunosuppressive protocol in our program remained constant. This would allow for identification of a group of patients with no CMV disease (Controls), appropriately matched to the Cases for immunosuppression, duration posttransplantation, as well as age and sex. Immunosuppression for Cases and Controls consisted of routine administration of the T-cell depleting antibody OKT3 administered at 5 mg/kg for five consecutive days after transplant. Maintenance immunosuppression consisted of either cyclosporine (the majority of cases) or tacrolimus; azathioprine or mycophenolate mofetil; and corticosteroids administered at diminishing dose during the initial year after transplant. All patients (cases and controls) were receiving potentially leukopenogenic drugs, trimethoprim-sulfamethoxazole and H2 antagonists, at the time of analysis as part of our routine standard of care. CMV prophylaxis consisted of intravenous ganciclovir administered at 5 mg/kg/day during the initial 28 days after transplant. The diagnostic criteria for CMV disease were based on the following criteria: presentation with organ dysfunction plus confirmation of CMV infection by histological diagnosis, positive culture and/or positive CMV PCR; or presentation with a viral syndrome plus positive CMV culture or PCR. From a total of 405 heart transplant recipients during this period, twenty Cases were identified who met the criteria for diagnosis of acute CMV disease. A control group of patients with no CMV disease was selected by the research nurse coordinator who was provided with criteria for identifying and selecting the control patients within the timeframe of transplant of the cases. The criteria for selecting controls were: being within the age range, and gender distribution of the cases, and having received similar immunosuppressive regimens posttransplant. For the Cases, the total and differential leukocyte counts, platelets and hemoglobin were recorded at two time points prior to the diagnosis and initiation of treatment for CMV disease (3-4 weeks and 1 week), and then on the day of diagnosis of CMV disease. For Controls, the total and differential leukocyte counts, platelets and hemoglobin were recorded at three time points, matched to the Cases for the duration posttransplant. The doses of immunosuppressive drugs at these time points were recorded for evaluation of potential effects due to changes in drug doses.
To examine the effect of subclinical CMV infection in the absence of any active disease, we studied two further cohorts of patients. The first Subclinical group (SubclinicalEarly) included 21 consecutive heart transplant recipients enrolled in a prospective cohort study of CMV infection. These patients underwent heart transplantation during 2002-2003, and were followed during the initial year after transplant with systematic monitoring of intracellular CMV infection, assayed monthly during the initial six months after transplant, and then at three-month intervals until 12 months after transplant. Blood samples collected in ethylenediamine tetraacetic acid (EDTA) anticoagulant were processed within 24 hours of collection by diluting with two volumes of phosphate-buffered saline (PBS) and separating into two fractions, peripheral blood mononuclear cells (PBMC; interface) and polymorphonuclear cells (PMN; pellet), using Histopaque (Sigma-Aldrich Inc., St Louis, MO). The samples were then analyzed for CMV DNA by qualitative nested polymerase chain reaction (qualPCR). Samples positive by qualitative PCR for CMV DNA were subjected to quantitative real-time (TaqMan) PCR as described below. Our prior analyses have indicated that over 90% of patients have at least one CMV DNA positive sample in both cell fractions analyzed during this follow-up period. Further, when the quantitative PCR analysis is performed, we have seen that levels varied from a minimum of Ͻ5 to a maximum of Ͼ4000 DNA copies/10 5 leukocytes. The majority of positive samples had low CMV DNA levels, such that overall median (25th to 75th percentile) levels were 34 (8 to 110) CMV genome copies/10 5 in PMNs and 17 (5 to 57) copies/10 5 in PBMCs (personal communication). For the purpose of this analysis, the data from the PMNs was used as no significant differences were detected between the two cell types.
Monitoring for CMV Infection: DNA Isolation, Nested PCR, and Real-Time PCR
Systemic CMV infection was monitored by separately analyzing CMV DNA PBMCs and PMNs, using a nested PCR followed by quantification of the positive samples by realtime PCR. DNA was isolated from 5ϫ10 5 PMN of each patient at each sample point, by lysing the cells overnight at 60°C in 250 l buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.0), 2 mM MgCl 2 , 0.45% NP40, 0.45% between 20, and 100 g/ml proteinase K. Subsequently, the samples were boiled for five min, incubated on ice for five min and stored at Ϫ80°C until use.
Nested PCR was performed using a PCT-100 Thermal Cycler (MJ Research, Reno, NV). The primers used for the nested PCR are located in the region coding for the IE-1 protein. The initial amplification was done with primers in exon 2, IEP2AII: 5Ј-ATG GAG TCC TCT GCC AAG AGA AAG ATG GAC-3Ј and exon 4, IEP4BII: 5Ј-CAA TAC ACT TCA TCT CCT CGA AAG G-3Ј. Primers for the second PCR are both located in exon 3, IEP3A: 5Ј-TCT GCC AGG ACA TCT TTC TC-3Ј and IEP3B: 5Ј-GTG ACC AAG GCC ACG ACG TT-3Ј. For the first PCR, 5 l of extracted PMN DNA was added to 45 l reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 (Roche Diagnostics Corporation, Indianapolis, IN), 200 M of each dNTP (Invitrogen Corporation, Carlsbad, CA), 1 U taq polymerase (Roche Diagnostics Corporation), and 1 M of each primer. For the second PCR, 5 l out of the first PCR was added to 45 l reaction mixture as used for the initial PCR. The PCR reactions were layered with 50 l of mineral oil. Conditions for both PCRs were, one cycle of 94°C for three min followed by 30 cycles of one min denaturation at 94°C, one min annealing at 62°C, a two min extension at 72°C, and a final extension step of seven min at 72°C.
After PCR, each sample was electrophoresed through a 2% agarose gel, containing 0.2 g/ml ethidium bromide and amplicons were visualized on an ultraviolet transilluminator.
The viral load in the positive samples, detected by nested PCR, was quantified using the SYBR Green real-time PCR method. Real-time PCR was performed in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA). A 5-l sample was added to 45 l reaction mix containing 25 l SYBR Green PCR Master Mix (Applied Biosystems) and 10 pmol of each primer. The primers used for the real-time PCR are also located in the gene encoding the IE1 protein, exon 2, IE1-2F: 5Ј-TCG TTG GAA TCC TCG GTC A-3Ј and IE1-2R: 5Ј-GGC CGA AGA ATC CCT CAA AA-3Ј. Conditions for the real-time PCR were: incubation at 50°C for two min to enable uralic N'-glycosylase (in master mix) to break down possible present amplicons, 94°C for 10 min to activate AmpliTaq Gold polymerase, followed by 40 cycles of 15 seconds denaturation at 94°C, and one min annealing and extension at 60°C. A standard curve of serial dilutions of known amounts of plasmid DNA was used to determine the copy numbers in the samples. Specificity of the amplified products was determined by dissociation curve analysis.
CMV infection was defined by the detection of positive PCR on PMN sample during the follow-up period. CMV infection burden was classified based on the frequency of CMV DNA positive samples and on the DNA copy number detected. Patients were considered to have experienced a highgrade infection when multiple positive results were detected, with at least one sample with a CMV DNA copy number higher than the 75th percentile of the copy number detected in the study population. All other patients with any CMV positive result were considered to have had a low-grade infection, whereas those in whom all the PMN samples resulted negative for CMV DNA were considered as free from CMV infection.
For the purpose of the present analysis, for each patient we identified time points of no CMV infection (CMV PCR negative by qualitative), onset of CMV DNA detection, and peak CMV DNA levels, and obtained white blood cell (WBC) and differential counts at those specific time points. In the second subclinical group (Subclinical Late, nϭ22) The presence of CMV DNA (by qualitative PCR) in peripheral blood leukocytes, and WBC and differential counts were measured in stable long-term survivors (1-9 years posttransplant) undergoing routine annual evaluation. None of these patients had any evidence of acute rejection or other infections. The protocol was approved by Stanford Institutional Review Board (IRB) for conduct of studies in human subjects.
Statistical Analysis
Results are expressed as meansϮstandard deviation. Differences in leukocyte counts between the three time points and between groups were assessed using paired and unpaired student t-tests, respectively. Differences in clinical parameters between the Cases, Subclinical-early, and Subclinicallate groups were assessed using analysis of variance (ANOVA) with Bonferroni corrections for multiple comparisons; a P value of less than 0.05 was considered to be significant.
RESULTS
Patient Demographics
The demographic characteristics of the Cases, Controls, Subclinical-Early, and Subclinical-Late groups are shown in Table 1 . Age, sex distribution, and duration posttransplant were similar across the groups, except for a longer duration posttransplant in the Subclinical-late group. The distribution of donor/recipient CMV serological status shows a high representation of Dϩ/RϪ patients in the Cases (11/ 20), consistent with the known high risk of this serological (8/20 in the Cases; 2/20 in the Controls; 4/22 Subclinical-late; and none in the Subclinical-early group). Cyclosporine was the most frequently used calcineurin antagonist (see Table 1 for distribution among the four cohorts). The average daily doses of MMF, cyclosporine, and tacrolimus were similar across the groups. However, average daily dose of prednisone was higher in the Cases compared to the Controls and Subclinical Early and Late patients.
Measurements of Total and Differential Leukocyte Counts Comparing MMF and Azathioprine Treated Patients
Considering the Cases and Controls as a whole, the average total leukocyte cell count did not differ between MMF and azathioprine-treated patients (5.9Ϯ2.7ϫ10 3 /L vs. 5.1Ϯ2.1ϫ10 3 /L; Table 2 ). Within the Controls, total leukocyte counts at baseline and at follow-up were lower in azathioprine compared to MMF treated patients. Within the Cases, total leukocyte counts at baseline were lower in the MMF compared to the azathioprine group, but at follow-up (study 3, see Table 2 ) were similar in the two treatment groups. Table 3 compares the total leukocyte count measured prior to and at the time of diagnosis of CMV disease in the patients who developed CMV disease (Cases); in the control group (Controls) at time points posttransplant similar to the Cases; in patients with subclinical infection followed during the first year of transplant (Subclinical-Early); and in longterm stable asymptomatic patients, positive for CMV DNA by PCR (Subclinical Infected-Late). In the Cases, total leukocyte count decreased progressively compared to measurements three to four weeks prior to diagnosis of CMV disease. In the Controls, total leukocyte count remained unchanged over the three time points studied. In the Subclinical-Early patients, total leukocyte count decrease from baseline, reaching a nadir at the time of peak CMV DNA level. Additionally, subsequent total leukocyte count increased coincident with the decline of CMV DNA levels (WBC count averageϭ5.2ϫ10 3 /uL at peak DNA CMV level versus 6.2ϫ10
Measurements of Leukocyte Counts at Baseline and Follow-up in the Cases, Controls, Subclinical Early, and Subclinical Late Groups
3 /uL at decline of CMV level. In the long-term patients, total leukocyte count did not differ significantly between CMV DNA positive and CMV DNA negative patients (data not shown). In the Subclinical-early and in the long-term patients, WBC was significantly higher than in the patients with active CMV disease (Cases).
Analysis of the leukocyte differential counts (Cases and Subclinical-early groups) revealed that the decline in WBC was due to an absolute reduction in the numbers of neutrophils and monocytes. Neutrophils declined from 4.4ϫ10 3 /uL (78%) to 2.5ϫ10 3 /uL (69%) (PϽ0.05) and monocytes declined from 0.6ϫ10 3 /uL (11%) to 0.3ϫ10 3 /uL (7.5%) (PϽ0.05).
Effect of CMV Disease on Platelet Count and Hemoglobin
Platelet counts were in the normal range in Cases and Controls, and hemoglobin was slightly reduced. In the Cases, during time course of CMV disease, there was a downward trend in platelet count (229Ϯ78ϫ10 
DISCUSSION
The major findings of this study are: 1) in human heart transplant recipients the total leukocyte count decreases prior weeks prior to diagnosis of CMV disease for cases, at time point posttransplant matched to Cases for controls, and prior to detection of CMV DNA Subclinical-early; WBC 2: measured 1-2 weeks prior to diagnosis of CMV disease for Cases, at time point post transplant matched to Cases for Controls, and at onset of detection of CMV DNA for Subclinicalearly; WBC 3: measured on day of diagnosis of CMV disease for cases, at time point posttransplant matched to Cases for Controls, and at peak CMV DNA level for Subclinical-early. Subclinical-late was measured at annual evaluation (1-9 years posttransplant).
to the time of diagnosis of CMV disease; 2) the leukocyte populations most reduced during CMV disease are the neutrophils and monocytes; 3) the reduction in leukocyte count that occurs during CMV disease appears to be independent of immunosuppressive therapy; 4) subclinical CMV infection during the initial year after transplant is associated with a decline in leukocyte count; 5) subclinical infection in stable long-term heart transplant patients without disease is unassociated with a reduction in the leukocyte count.
In the clinical practice of solid organ transplantation, leucopenia has been recognized as one of the clinical manifestations of CMV disease. However, there is paucity of information documenting the frequency, time course, and clinical relevance of leucopenia in the context of CMV infection and disease. Additionally, there is little data on leucopenia and CMV disease in heart transplant patients. This information could be important for the early recognition and diagnosis of CMV disease; and for improved understanding of the role of subclinical infection in predicting either acute CMV disease or associated indirect effects of CMV such as graft vascular disease and/or opportunistic infections. Knowledge of the relationship between leucopenia and CMV infection may also assist in clinical decisions regarding adjustment of immunosuppressive drugs that increase the risk of CMV disease and also predispose to leucopenia. Aside from these practical applications discussed below, understanding the role of leucopenia in CMV disease compared to subclinical CMV infection may provide new research directions on the mechanisms accounting for the indirect effects of CMV such as acute rejection and allograft vasculopathy.
The current study provides documentation that in human heart transplant recipients the total leukocyte count decreases prior to the time of diagnosis of CMV disease. Leucopenia is frequently listed as a manifestation of CMV disease, yet documentation of this anecdotal knowledge is sparse in the literature. A Medline search failed to provide any study on the time course of leucopenia as it relates to CMV disease or subclinical infection. Studies in kidney and heart transplant recipients have addressed the question of leucopenia in the context of immunosuppressive regimens that include mycophenolate mofetil because this drug has been associated with increased risk for CMV disease (15, 16) . One such study reported that patients receiving high doses of MMF (3 g/day) plus conventional doses of cyclosporine, displayed leucopenia during CMV disease, while in other patients receiving similar doses of MMF (3 g/day) but lower doses of cyclosporine, leucopenia was unassociated with CMV disease (15) . Our findings are in part consistent with the observations from this study of kidney transplant recipients, in that leucopenia was indeed observed in the context of CMV disease. However, in our study of heart transplant patients, we did not observe any difference in MMF dose between patients who developed CMV disease, and those who did not. In contrast, among patients receiving azathioprine, the average dose of azathioprine was higher in the patients who developed CMV disease. It should be noted that the number of patients on azathioprine constituted only a third of total Cases and Controls, and none of the Subclinical-early group. Overall WBC was not significantly different between azathioprine-and MMFtreated patients. There were, however, subtle differences with baseline WBC counts in patients who developed CMV disease being lower in MMF-treated patients. Our study design involving paired analysis of the individual patient's drop in WBC, provided confirmation that leucopenia occurs in the context of CMV disease. Importantly, our results suggest that leucopenia precedes CMV disease, an observation that is of direct relevance to patient management in terms of early diagnosis and treatment. Additionally, this clinically important observation provided the rationale to explore the relationship of leucopenia to subclinical CMV infection, the findings of which are discussed below.
We observed that the leukocyte populations most reduced during CMV disease are the neutrophils and monocytes, while lymphocyte counts remained stable. These observations are consistent with the pathobiology of human CMV (HCMV), which include its evolution of mechanisms for avoiding detection by the host immune system. Furthermore impaired hematopiesis is documented in animal models of CMV infection (17) . This effect of CMV could explain the decrease in neutrophils and monocytes we observed in this study. Importantly, it could account for the immunosuppressive state that is frequently reported in the context of CMV infection in solid organ transplant recipients (18) . Such immunosuppressive effect of the virus is permissive for opportunistic infections that have been shown to be decreased with therapies directed at inhibiting CMV replication. Specifically, some studies have reported decreased fungal infection rates in patients treated with ganciclovir or valacyclovir as prophylaxis for CMV infection (14) . Our observation of a decrease in monocytes during the CMV disease is unexplained because one commonly thinks of herpes viruses causing monocytosis in immunocompetent subjects. The question of whether this new finding is related to the effect of viral infection in the setting of an immunocompromised host warrants further investigation.
In the current study, we observed that subclinical infection in during the first year after transplant was associated with a reduction in the total leukocyte count, despite the absence of any clinical symptoms or signs of CMV disease. The rise in CMV DNA levels generally occurred after the completion of CMV prophylaxis, typically after the fourth month posttransplant. Recent studies have drawn attention to the changing epidemiology of CMV disease in solid organ transplantation (19) . In particular, whereas the rate of CMV disease appears to have decreased with the use of prophylactic regimens, the proportion of late cases occurring beyond 6 months after transplant have increased. Importantly, these late cases appear to present in an atypical manner, with the typical manifestation such as leucopenia being less frequently observed. In the current study, we observed a decline in the total leukocyte count that was coincident with the rise and fall in CMV DNA copies/10 5 PMN (preWBC drop: 15Ϯ12 copies/10 5 PMN; at WBC nadir: 110Ϯ70 copies/10 5 PMN; at recovery of WBC 40Ϯ15 copies/10 5 PMN). It is important to note that the nadir of the leukocyte count measured was 5.2Ϯ0.03ϫ10 3 /uL, a level that would not be recognized as leucopenia per se. Importantly, the PCR primer used detects CMV early immediate gene expression, indicating active rather than latent virus. Thus our observation of a significant decrease in WBC count that preceded peak elevations of CMV DNA in peripheral blood monocytes and neutrophils suggests that CMV activation is closely linked to the decrease in the total leukocyte count, even in the absence of clinical disease. This observation has important implications for understanding the pathophysiology of CMV disease. These data indicate that there must be additional viral-host interactions that contribute to the reduction of WBC, either the CMV itself, mutations of it, or other interactions it may have with its host.
Study Limitations
The analysis of Cases and Controls represent a retrospectively identified cohort and therefore subject to potential selection bias that may contribute to observed differences the two groups. Also, there may have been subtle changes in patient management, including the immunosuppressive regimens and doses that could significantly impact on the development of CMV disease, even though all efforts were made to select Controls that were matched to Cases with respect to transplantation within a similar immunosuppression era at our institution. These limitations are to some extent mitigated by the findings from the Subclinical Early group that were prospectively followed within a standardized immunosuppressive protocol. However, the observation of a decline in WBC in subclinically infected patients during the first year after heart transplantation is consistent with the observation in patients with clinically overt CMV disease. Another important limitation is the fact that pretransplant donor/recipient serological status varied among the groups studied, with the Cases having the highest proportion of Dϩ/RϪ patients. Because Dϩ/RϪ patients are known to be at high risk for primary CMV infection and CMV disease, many of the observations reported in this group could be related to their CMV serological status. Another important limitation is the widely variable immunosuppressive regimens in the cases and controls. This is in part due to the wide time span from which patients were drawn, and reflects changes in immunosuppressive regiments over time. Additionally, the use of Tcell depleting regimens could have contributed to high incidence of CMV infection, both clinically apparent and subclinical. However, since OKT3 was used in all Cases and Controls, it is unlikely that the effects of this form of induction therapy can explain the differences in WBC between these groups. Due to the limitation of sample size, this study cannot address the important clinical issue of whether the immunosuppressive regimen per se determines whether or not a patient with CMV replication will develop leucopenia.
